FDA Rejects TransEnterix’ 510(k) For Surgibot
This article was originally published in Clinica
Executive Summary
The US FDA has notified TransEnterix that the SurgiBot single-port, robotically enhanced laparoscopic surgical platform does not meet the criteria for substantial equivalence, according to the company.